Experimental and Clinical Pharmacology

Perceptions of risk - a legal perspective

John McPhee
  • 1 October 2002
Experimental and Clinical Pharmacology

New treatments for advanced and metastatic colorectal cancer - clinical applications

Stephen Clarke
  • 1 October 2002
Letters to the Editor

Dental patients receiving warfarin therapy

Alastair N. Goss, Glen Carter, 3fc89ffb74c780df, 1f6fb1005583ea0a
  • 1 October 2002
Editorial

Can we afford intensive management of diabetes?

Brita Pekarsky, Ben Ewald
  • 1 October 2002
Letters to the Editor

The evidence-relevance gap

Brian Duffy, B.W. Griffiths, Paul Neeskens
  • 1 October 2002
Letters to the Editor

The heavy drinker in primary care

Kevin McNamara, Greg Whelan
  • 1 October 2002
Letters to the Editor

Medicinal mishaps

Glenn Valoppi, Simone Taylor, Mahesan Anpalahan, Consultant Physician Western Hospital, Melbourne
  • 1 October 2002
Patient support organisations

Retina Australia

  • 1 October 2002
Letters to the Editor

Discontinuation of naproxen suspension

Madlen Gazarian, Kevin Murray, Don Roberton, David Kingston
  • 1 October 2002
Experimental and Clinical Pharmacology

New drugs for colorectal cancer - mechanisms of action

Laurent P. Rivory, Clinical Senior Lecturer
  • 1 October 2002
Feature

How we write about new drugs

J.S. Dowden
  • 1 October 2002
Letters to the Editor

Insulins in 2002

Ross Philpot, Pat Phillips
  • 1 October 2002
Article

Drug treatment of macular degeneration

Robyn Guymer, Medical Retinal Consultant
  • 1 October 2002
NEW DRUGS
Reboxetine mesylate
  • 1 October 2002
Azathioprine
  • 1 October 2002
Peginterferon alfa-2b
  • 1 October 2002
Ipratropium bromide
  • 1 October 2002
Amisulpride
  • 1 October 2002
Modafinil
  • 1 October 2002

IF YOU PRESCRIBE SUBSCRIBE

If you’re a health professional, subscribe to receive regular email updates from Australian Prescriber

Subscribe